RayKnowChina Research Map
Shortlist0

Not yet recruitingMultiple myelomaPhase 2

Registered title, quoted from ClinicalTrials.gov

CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07830485, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Agree to use effective contraception from the date of signing informed consent throughout study treatment and for at least 3 months after the last dose of study treatment.

    Inclusion criterion 28

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 3-4;

    Inclusion criterion 6

  4. Total bilirubin <1.5 × upper limit of normal (ULN), except for participants with Gilbert syndrome, who must have total bilirubin <3 × ULN;

    Inclusion criterion 13

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN.

    Inclusion criterion 14

    White blood cell (WBC) count ≥1.5 × 10\^9/L;

    Inclusion criterion 17

    Absolute neutrophil count (ANC) ≥1.0 × 10\^9/L;

    Inclusion criterion 18

    Hemoglobin ≥70 g/L;

    Inclusion criterion 19

    Platelet count ≥75 × 10\^9/L if bone marrow plasma cells are <50%, or ≥50 × 10\^9/L if bone marrow plasma cells are ≥50%.

    Inclusion criterion 20

    At least 2 weeks between the last red blood cell (RBC) transfusion and hemoglobin assessment at screening;

    Inclusion criterion 23

    At least 1 week between the last platelet transfusion and platelet assessment at screening.

    Inclusion criterion 24

  5. Human immunodeficiency virus (HIV) infection;

    Exclusion criterion 11

    Active hepatitis B infection (HBV DNA positive);

    Exclusion criterion 12

    Active hepatitis C infection (HCV RNA positive);

    Exclusion criterion 13

    Active pulmonary tuberculosis, as evidenced by chest imaging or other relevant examinations within 3 months before screening or during the screening period;

    Exclusion criterion 15

  6. Have a negative serum pregnancy test at screening; and

    Inclusion criterion 27

    Pregnant or breastfeeding women.

    Exclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07830485, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Able to understand and voluntarily sign a written informed consent form (ICF).
  • Age 18 to 75 years.
  • Newly diagnosed symptomatic multiple myeloma according to International Myeloma Working Group (IMWG) criteria. Patients who have received no more than two cycle of anti-myeloma therapy before enrollment are eligible.
  • Not planned to undergo autologous stem cell transplantation as first-line treatment and meeting at least one of the following criteria, including but not limited to:
  • Age ≥65 years;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 3-4;
  • Considered unable to tolerate autologous stem cell transplantation based on investigator assessment.
  • Measurable disease, defined by at least one of the following:
  • Serum M-protein ≥10 g/L by serum protein electrophoresis (SPEP); for IgA or IgD myeloma, quantitative IgA or IgD levels may be used instead;
  • Urine M-protein ≥200 mg/24 hours;
  • If neither serum nor urine M-protein meets the above criteria, involved serum free light chain (FLC) ≥100 mg/L with an abnormal serum FLC ratio (normal range: 0.26-1.65).
  • Adequate hepatic function, defined as:
  • Total bilirubin <1.5 × upper limit of normal (ULN), except for participants with Gilbert syndrome, who must have total bilirubin <3 × ULN;
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN.
  • Adequate renal function, defined as creatinine clearance ≥30 mL/min calculated using the Cockcroft-Gault formula.
  • Hematologic parameters within 7 days prior to screening meeting the following criteria:
  • White blood cell (WBC) count ≥1.5 × 10\^9/L;
  • Absolute neutrophil count (ANC) ≥1.0 × 10\^9/L;
  • Hemoglobin ≥70 g/L;
  • Platelet count ≥75 × 10\^9/L if bone marrow plasma cells are <50%, or ≥50 × 10\^9/L if bone marrow plasma cells are ≥50%.
  • Participants receiving hematopoietic growth factor support, including erythropoietin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or thrombopoietic agents (e.g., eltrombopag, thrombopoietin, or interleukin-11), must have an interval of at least 2 weeks between the last administration of growth factor support and screening assessment.
  • Participants receiving blood product transfusions must meet the following requirements:
  • At least 2 weeks between the last red blood cell (RBC) transfusion and hemoglobin assessment at screening;
  • At least 1 week between the last platelet transfusion and platelet assessment at screening.
  • Able and willing to receive protocol-recommended prophylactic anticoagulation therapy.
  • Female participants of childbearing potential must:
  • Have a negative serum pregnancy test at screening; and
  • Agree to use effective contraception from the date of signing informed consent throughout study treatment and for at least 3 months after the last dose of study treatment.

Male participants, including those who have undergone vasectomy, must agree to use condoms during sexual intercourse with women of childbearing potential and must not plan to father a child from the date of signing informed consent throughout study treatment and for at least 3 months after the last dose of study treatment.

Exclusion Criteria:

  • Diagnosis of smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia, POEMS syndrome, amyloidosis, or primary or secondary plasma cell leukemia.
  • Central nervous system (CNS) involvement or clinical evidence of leptomeningeal involvement.
  • Known intolerance, hypersensitivity, allergy, or contraindication to daratumumab, lenalidomide, or CM336.
  • Severe and/or uncontrolled cardiovascular disease, including:
  • Unstable angina;
  • Symptomatic congestive heart failure;
  • Myocardial infarction within 6 months prior to enrollment;
  • Severe and uncontrolled cardiac arrhythmias;
  • Any other cardiovascular or cerebrovascular condition deemed by the investigator to make participation inappropriate.
  • Active infection, including:
  • Human immunodeficiency virus (HIV) infection;
  • Active hepatitis B infection (HBV DNA positive);
  • Active hepatitis C infection (HCV RNA positive);
  • Active or latent syphilis infection (Treponema pallidum antibody positive);
  • Active pulmonary tuberculosis, as evidenced by chest imaging or other relevant examinations within 3 months before screening or during the screening period;
  • Concurrent malignancy or any serious concomitant disease that, in the investigator's judgment, could compromise participant safety or interfere with completion of the study.
  • Pregnant or breastfeeding women.
  • Expected life expectancy of less than 6 months.
  • Any active gastrointestinal disorder that may impair the participant's ability to swallow oral medication or may interfere with absorption of study treatment.
  • Major surgery within 2 weeks prior to enrollment (e.g., surgery requiring general anesthesia), incomplete recovery from prior surgery, or planned major surgery during study participation. Kyphoplasty and vertebroplasty are not considered major surgery. Participants undergoing procedures under local anesthesia may be eligible.
  • Receipt of a live attenuated vaccine within 4 weeks before the first dose of study treatment.
  • Any active severe psychiatric disorder, medical condition, symptom, or other circumstance that, in the investigator's judgment, may interfere with treatment, protocol compliance, or the ability to provide informed consent.
  • Inability or unwillingness to provide written informed consent.

Quoted from ClinicalTrials.gov, NCT07830485, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07830485, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07830485